Which class of drugs is preferred for blood pressure control in CKD with proteinuria?

Which class of drugs is preferred for blood pressure control in CKD with proteinuria?

• A. ACE inhibitors
• B. NSAIDs
• C. Beta-blockers
• D. Calcium channel blockers

Answer: (A)

When blood pressure treatment is needed in chronic kidney disease with proteinuria, start by targeting the renin-angiotensin system. Blocking this system with an ACE inhibitor provides renal protection beyond simply lowering blood pressure: it reduces intraglomerular pressure, lowers protein leakage into urine, and slowing the progression of kidney damage. This proteinuric reduction is a key goal because persistent proteinuria is a strong predictor of CKD progression and cardiovascular risk. ACE inhibitors work by dilating the efferent arteriole of the glomerulus, which decreases the pressure inside the glomerular capillaries and reduces the amount of protein that leaks into the urine. This dual effect—BP reduction plus nephroprotection—makes them the preferred choice in CKD with proteinuria. If a patient cannot tolerate ACE inhibitors due to cough or risk of angioedema, an ARB can be used as an alternative, as it provides similar renoprotective benefits. Be mindful that initiating therapy requires monitoring of kidney function and potassium. In some cases, especially with bilateral renal artery stenosis or existing hyperkalemia, ACE inhibitors can worsen kidney function or cause dangerous potassium elevations, necessitating careful evaluation or avoidance. NSAIDs can worsen kidney function by constricting the afferent arteriole and are generally avoided in CKD. Beta-blockers and certain calcium channel blockers may effectively lower blood pressure, but they do not offer the same protective effect on proteinuria and long-term kidney outcomes as ACE inhibitors (though they may be used as additional agents to achieve BP targets).

When blood pressure treatment is needed in chronic kidney disease with proteinuria, start by targeting the renin-angiotensin system. Blocking this system with an ACE inhibitor provides renal protection beyond simply lowering blood pressure: it reduces intraglomerular pressure, lowers protein leakage into urine, and slowing the progression of kidney damage. This proteinuric reduction is a key goal because persistent proteinuria is a strong predictor of CKD progression and cardiovascular risk.

ACE inhibitors work by dilating the efferent arteriole of the glomerulus, which decreases the pressure inside the glomerular capillaries and reduces the amount of protein that leaks into the urine. This dual effect—BP reduction plus nephroprotection—makes them the preferred choice in CKD with proteinuria. If a patient cannot tolerate ACE inhibitors due to cough or risk of angioedema, an ARB can be used as an alternative, as it provides similar renoprotective benefits.

Be mindful that initiating therapy requires monitoring of kidney function and potassium. In some cases, especially with bilateral renal artery stenosis or existing hyperkalemia, ACE inhibitors can worsen kidney function or cause dangerous potassium elevations, necessitating careful evaluation or avoidance.

NSAIDs can worsen kidney function by constricting the afferent arteriole and are generally avoided in CKD. Beta-blockers and certain calcium channel blockers may effectively lower blood pressure, but they do not offer the same protective effect on proteinuria and long-term kidney outcomes as ACE inhibitors (though they may be used as additional agents to achieve BP targets).